A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma

Phase 2 Completed 36 enrolled MedImmune LLC

RandomizedSingle-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the safety and tolerability of escalating multiple SC doses of MEDI-528 in adult patients with mild persistent asthma.

Timeline

Start: 2007-07
Primary completion: 2008-07
Completion: 2008-09

Publications

Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, Robbie GJ, White WI, White B, Molfino NA; MEDI-528 Clinical Trials Group. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med. 2011 Feb 28;11:14. doi: 10.1186/1471-2466-11-14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ENOKIZUMAB	Monoclonal antibody	0.3 mg/kg	Subcutaneous
Subject	ENOKIZUMAB	Monoclonal antibody	1 mg/kg	Subcutaneous
Subject	ENOKIZUMAB	Monoclonal antibody	3 mg/kg	Subcutaneous

A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma

Summary

Timeline

Publications

Drugs

Indications